Table 2.
Moxiflocaxin-based first-line treatment regimens in H. pylori infection.
| First author Year | Study design | Patients (n) | Regimens | Treatment duration (days) | Eradication rate, intention to treat (%) (n) | Side effects (%) |
|---|---|---|---|---|---|---|
| Di Caro et al. [2002a] | Prospective | 120 | MOX 400 mg od | 7 | 23 (9/40) | 8 |
| randomized | LAN 30 mg od, MOX 400 mg od | 7 | 33 (13/40) | 13 | ||
| LAN 30 mg od, MOX 400 mg od, CLA 500 mg bid | 7 | 90 (36/40) | 13 | |||
| Nista [2005] | Prospective randomized | 320 | ESO 20 mg bd, MOX 400 mg od, AMO 1000 mg bid | 7 | 88 (70/80) | 13 |
| ESO 20 mg bid, MOX 400 mg od, TIN 500 mg bid | 7 | 90 (72/80) | 14 | |||
| ESO 20 mg bid, CLA 500 mg bid, AMO 1000 mg bid | 7 | 73 (58/80) | 33 | |||
| ESO 20 mg bid, CLA 500 mg bid, TIN 500 mg bid | 7 | 75 (60/80) | 36 | |||
| Bago [2007] | Prospective randomized | 277 | LAN 30 mg bid, MOX 400 mg od, MET 400 mg bid | 7 | 94 (58/62) | 8 |
| LAN 30 mg bid, MOX 400 mg od, AMO 1000 mg bid | 7 | 86 (57/66) | 5 | |||
| LAN 30 mg bid, CLA 500 mg bid, MET 400 mg bid | 7 | 70 (50/71) | 18 | |||
| LAN 30 mg bid, CLA 500 mg bid, AMO 1000 mg bid | 7 | 78 (61/78) | 9 | |||
| Sezgin [2007] | Prospective | 71 | PAN 40 mg bid, MOX 400 mg od, AMO 1000 mg bid | 14 | 42 (30/71) | 30 |
| Kilic [2008] | Prospective randomized | 120 | RBC 400 mg bid, CLA 500 mg bid, AMO 1000 mg bid | 14 | 77 (23/30) | 37 |
| RBC 400 mg bid, MOX 400 mg od, AMO 1000 mg bid | 14 | 67 (20/30) | 42 | |||
| ESO 40 mg bid, CLA 500 mg bid, AMO 1000 mg bid | 14 | 63 (19/30) | 57 | |||
| ESO 40 mg bid, MOX 400 mg od, AMO 1000 mg bid | 14 | 53 (16/30) | 70 | |||
| Sacco [2009] | Prospective randomized | 399 | ESO 20 mg bid, MOX 400 mg bid, AMO 1000 mg bid | 10 | 90 (85/94) | 12 |
| ESO 20 mg bid, MOX 400 mg bid, AMO 1000 mg bid | 7 | 80 (82/102) | 16 | |||
| ESO 20 mg bid, MOX 400 mg bid, AMO 1000 mg bid | 5 | 71 (70/98) | 12 | |||
| ESO 20 mg bid, MOX 400 mg od, AMO 1000 mg bid | 10 | 80 (84/105) | 13 | |||
| Bago [2010] | Prospective randomized | 150 | LAN 30 mg bid, MOX 400 mg od, AMO 1000 mg bid | 7 | 76 (57/75) | 15 |
| LAN 30 mg bid, MOX 400 mg od, AMO 1000 mg bid | 10 | 84 (63/75) | 24 |
*
No data.
AMO, amoxicillin; bid, twice daily; CLA, clarithromycin; ESO, esomeprazole; LAN, lansoprazole; MET, metronidazole; MOX, moxifloxacin; od, once daily; PAN, pantoprazole; RBC, ranitidine bismuth citrate; TIN, tinidazole.